Objetivo
TransQST will develop a Quantitative Systems Toxicology (QST) approach, employing pre-existing data where possible, in order to yield new mechanistic insight into drug-induced toxicity. A central tenet of our programme will be to ensure the human physiological and pharmacological relevance of any test system that has been (or will be) used for generating the input data for modelling. By adopting this approach, we will be able to accurately interpret what happens when test systems are perturbed by drug exposure, and ensure translatability of modelling tools. Mechanistic translational biomarkers are a core aspect of our approach and will be applied in parallel with evidence for understanding how to develop, model and apply such biomarkers in a QST setting. The project is structured in 8 work packages to provide the following outcomes: curate the best available experimental data suitable for modelling adverse drug reactions; provide fit-for-purpose QST models that will address key toxicity measures for liver, kidney, heart and GI-tract; provide quantitative risk assessment for off-target toxicity in man based on in vitro and in vivo models; provide a quantitative mechanistic read-across from species (in vivo and in vitro) currently used for the toxicological evaluation of a new drug; provide definition and applicability of the human physiological relevance of preclinical test systems; provide a battery of translational biomarkers that can be used for quantitative read-across from in vitro systems to man and which relate to intracellular pathways (and systems) relevant to drug toxicity. Led by the University of Liverpool, TransQST brings together 14 partners, characterized by their scientific rigour and proven track record. Collectively they will enable achievement of the goals of the call, thanks to their complementarity, proven ability to work together (and with EFPIA partners), and their understanding of how to ensure the relevance of QST to human biology.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacydrug safety
- medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmia
- medical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactions
- medical and health sciencesbasic medicinetoxicology
Palabras clave
Programa(s)
Convocatoria de propuestas
H2020-JTI-IMI2-2015-06-two-stage
Consulte otros proyectos de esta convocatoriaRégimen de financiación
RIA - Research and Innovation actionCoordinador
L69 7ZX Liverpool
Reino Unido
Ver en el mapa
Participantes (23)
2311 EZ Leiden
Ver en el mapa
08003 Barcelona
Ver en el mapa
28006 Madrid
Ver en el mapa
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.
6200 MD Maastricht
Ver en el mapa
69117 Heidelberg
Ver en el mapa
OX1 2JD Oxford
Ver en el mapa
EC2Y 5EB London
Ver en el mapa
1010 Wien
Ver en el mapa
La participación finalizó
52074 Aachen
Ver en el mapa
44139 Dortmund
Ver en el mapa
3512 KC Utrecht
Ver en el mapa
3015 GD Rotterdam
Ver en el mapa
65205 Wiesbaden
Ver en el mapa
RG21 4FA Basingstoke
Ver en el mapa
94250 GENTILLY
Ver en el mapa
151 85 Sodertaelje
Ver en el mapa
TW89GS Brentford
Ver en el mapa
92284 Courbevoie
Ver en el mapa
2340 Beerse
Ver en el mapa
02200 Espoo
Ver en el mapa
55218 Ingelheim
Ver en el mapa
69120 Heidelberg
Ver en el mapa
W2 6BD London
Ver en el mapa